Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$93.50 AUD
Change Today +0.70 / 0.75%
Volume 349.7K
As of 11:37 PM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

csl ltd (CSL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - A$96.60
52 Week Low
08/8/14 - A$63.77
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CSL LTD (CSL)

Related News

No related news articles were found.

csl ltd (CSL) Related Businessweek News

View More BusinessWeek News

csl ltd (CSL) Details

CSL Limited is engaged in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including vaccines to protect against viral and bacterial diseases; pharmaceuticals to treat a range of human medical conditions; diagnostic products to determine compatibility of donor-recipient blood in transfusion settings; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment is engaged in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

12,196 Employees
Last Reported Date: 08/12/14
Founded in 1916

csl ltd (CSL) Top Compensated Officers

Chief Executive Officer, Managing Director, E...
Total Annual Compensation: $3.1M
Chief Financial Officer
Total Annual Compensation: $1.6M
Chief Scientific officer and Director of R&D
Total Annual Compensation: $1.2M
Executive Vice President of Manufacturing Ope...
Total Annual Compensation: $1.1M
Executive Vice President of Legal, Group Gene...
Total Annual Compensation: $998.2K
Compensation as of Fiscal Year 2014.

csl ltd (CSL) Key Developments

G. Naylor to Lead CSL Limited's New Influenza Vaccine Business Planned for Launch at the Start of 2016

CSL Limited announced that Gordon Naylor will lead CSL's new global influenza vaccine business, which is planned for launch at the start of 2016. Mr. Naylor is currently the Company's Chief Financial Officer and has held executive management responsibility for CSL's existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012.

CSL Ltd. Presents at Credit Suisse 18th Annual Asian Investment Conference 2015, Mar-23-2015

CSL Ltd. Presents at Credit Suisse 18th Annual Asian Investment Conference 2015, Mar-23-2015 . Venue: Conrad Hotel, Pacific Place, 88 Queensway, Hong Kong, Hong Kong.

CSL Ltd. Reports Unaudited Consolidated Earnings Results for the Half Year Ended December 31, 2014; Provides Earnings Guidance for Fiscal 2015

CSL Ltd. reported unaudited consolidated earnings results for the half year ended December 31, 2014. The company increased net profit 7.2% to $692.2 million in the half-year ended December 31, 2014 from $645.7 million a year earlier. Revenues were up 5.6% to $2.8 billion from $2.7 billion. On a constant currency basis, net profit rose 9.1% to $705.0 million on sales revenue up 8.3% to $2.8 billion. Profit before income tax expense was $857.0 million compared to $802.4 million a year ago. Diluted earnings per share were 145.5 cents compared to 132.6 cents a year ago. Net cash inflow from operating activities was $656.0 million compared to $512.5 million a year ago. Payments for property, plant and equipment were $161.3 million compared to $170.4 million a year ago. Payments for intangible assets were $15.6 million compared to $18.6 million a year ago. Consolidated EBIT was $878.3 million and consolidated EBITDA was $968.9 million as compared to consolidated EBIT of $818.0 million and consolidated EBITDA of $912.2 million for the same period last year. The company continues to have a strong outlook; however, in light of current trading conditions the company has tempered its net profit after tax guidance for fiscal 2015 to approximately 10% at constant currency. This growth is prior to the inclusion of integration costs associated with the acquisition of the Novartis influenza business. Earnings per share growth is again anticipated to exceed profit growth. The company is tracking to spend between $430 million and $450 million for the full year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CSL:AU A$93.50 AUD +0.70

CSL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,822 JPY +4.00
Green Cross Corp/South Korea 204,500 KRW +3,000
Grifols SA €36.79 EUR -0.72
Shire PLC 5,540 GBp +35.00
Solvay SA €127.40 EUR -0.50
View Industry Companies

Industry Analysis


Industry Average

Valuation CSL Industry Range
Price/Earnings 25.8x
Price/Sales 6.3x
Price/Book 11.5x
Price/Cash Flow 25.0x
TEV/Sales 5.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CSL LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at